Inhibition of p38 MAPK during ischemia, but not reperfusion, effectively attenuates fatal arrhythmia in ischemia/reperfusion heart

Journal of Cardiovascular Pharmacology

Volumn 61, Issue 2, 2013, Pages 133-141

  Surinkaew, Sirirat ^a   Kumphune, Sarawut ^a,b   Chattipakorn, Siriporn ^a,c   Chattipakorn, Nipon ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b NARESUAN UNIVERSITY   (Thailand)

^c CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

arrhythmias; ischemia reperfusion injury; p38 MAPK

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CONNEXIN 43; CYTOCHROME C; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HEART ARRHYTHMIA; HEART INFARCTION SIZE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE FUNCTION; HEART VENTRICLE TACHYCARDIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REPERFUSION INJURY;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ARRHYTHMIAS, CARDIAC; CYTOCHROMES C; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; IMIDAZOLES; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PYRIDINES; RATS; RATS, WISTAR; TIME FACTORS; VENTRICULAR FUNCTION;

EID: 84873407517     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318279b7b1     Document Type: Article

References (45)

1. World Health Organization. World Health Statistics 2008. Available at http://www.who.int/entity/whosis/whostat/EN-WHS08-Full.pdf. Accessed November 2012.
2. See F, Kompa A, Krum H. P38 map kinase as a therapeutic target in cardiovascular disease. Drug Discov Today Ther Strateg. 1994;1:149-154.
3. Wang M, Tsai BM, Turrentine MW, et al. P38 mitogen activated protein kinase mediates both death signaling and functional depression in the heart. Ann Thorac Surg. 2005;80:2235-2241.
4. Lerner DL, Yamada KA, Schuessler RB, et al. Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. Circulation. 2000;101:547-552.
5. Ma XL, Kumar S, Gao F, et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation. 1999; 99:1685-1691.
6. Mackay K, Mochly-Rosen D. An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia. J Biol Chem. 1999;274:6272-6279.
7. Barancik M, Htun P, Strohm C, et al. Inhibition of the cardiac p38-mapk pathway by SB203580 delays ischemic cell death. J Cardiovasc Pharmacol. 2000;35:474-483.
8. Aleshin A, Sawa Y, Ono M, et al. Myocardial protective effect of FR167653; a novel cytokine inhibitor in ischemic-reperfused rat heart. Eur J Cardiothorac Surg. 2004;26:974-980.
9. Thomas CJ, Ng DC, Patsikatheodorou N, et al. Cardioprotection from ischaemia-reperfusion injury by a novel flavonol that reduces activation of p38 MAPK. Eur J Pharmacol. 2011;658:160-167.
10. Gysembergh A, Simkhovich BZ, Kloner RA, et al. P38 MAPK activity is not increased early during sustained coronary artery occlusion in preconditioned versus control rabbit heart. J Mol Cell Cardiol. 2001; 33:681-690.
11. Yada M, Shimamoto A, Hampton CR, et al. FR167653 diminishes infarct size in a murine model of myocardial ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 2004;128:588-594.
12. Kumphune S, Chattipakorn S, Chattipakorn N. Role of p38 inhibition in cardiac ischemia/reperfusion injury. Eur J Clin Pharmacol. 2012;68: 513-524.
13. Connelly KA, Prior DL, Kelly DJ, et al. Load-sensitive measures may overestimate global systolic function in the presence of left ventricular hypertrophy: A comparison with load-insensitive measures. Am J Physiol Heart Circ Physiol. 2006;290:H1699-H1705.
14. Lv X, Wan J, Yang J, et al. Cytochrome p450 omega-hydroxylase inhibition reduces cardiomyocyte apoptosis via activation of ERK1/2 signaling in rat myocardial ischemia-reperfusion. Eur J Pharmacol. 2008;596:118-126.
15. Ward KW, Prokscht JW, Azzaranot LM, et al. Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase. Xenobiotica. 2001;31:783-797.
16. Walker MJ, Curtis MJ, Hearse DJ, et al. The lambeth conventions: Guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc Res. 1988;22:447-455.
17. Curtis MJ, Walker MJ. Quantification of arrhythmias using scoring systems: An examination of seven scores in an in vivo model of regional myocardial ischaemia. Cardiovasc Res. 1988;22:656-665.
18. Brown DA, Aon MA, Akar FG, et al. Effects of 40-chlorodiazepam on cellular excitation-contraction coupling and ischaemia-reperfusion injury in rabbit heart. Cardiovasc Res. 2008;79:141-149.
19. Bohl S, Medway DJ, Schulz-Menger J, et al. Refined approach for quantification of in vivo ischemia-reperfusion injury in the mouse heart. Am J Physiol Heart Circ Physiol. 2009;297:H2054-2058.
20. Mersmann J, Latsch K, Habeck K, et al. Measure for measure-determination of infarct size in murine models of myocardial ischemia and reperfusion: A systematic review. Shock. 2011;35:449-455.
21. Yin C, Salloum FN, Kukreja RC. A novel role of microRNA in late preconditioning: Upregulation of endothelial nitric oxide synthase and heat shock protein 70. Circ Res. 2009;104:572-575.
22. Leducq N, Bono F, Sulpice T, et al. Role of peripheral benzodiazepine receptors in mitochondrial, cellular, and cardiac damage induced by oxidative stress and ischemia-reperfusion. J Pharmacol Exp Ther. 2003;306: 828-837.
23. Obame FN, Zini R, Souktani R, et al. Peripheral benzodiazepine receptorinduced myocardial protection is mediated by inhibition of mitochondrial membrane permeabilization. J Pharmacol Exp Ther. 2007;323:336-345.
24. Riess ML, Rhodes SS, Stowe DF, et al. Comparison of cumulative planimetry versus manual dissection to assess experimental infarct size in isolated hearts. J Pharmacol Toxicol Methods. 2009;60: 275-280.
25. Palee S, Weerateerangkul P, Surinkeaw S, et al. Effect of rosiglitazone on cardiac electrophysiology, infarct size and mitochondrial function in ischaemia and reperfusion of swine and rat heart. Exp Physiol. 2011; 96:778-789.
26. Kanlop N, Thommasorn S, Palee S, et al. Granulocyte colony-stimulating factor stabilizes cardiac electrophysiology and decreases infarct size during cardiac ischaemic/reperfusion in swine. Acta Physiol (Oxf). 2011; 202:11-20.
27. Tanno M, Bassi R, Gorog DA, et al. Diverse mechanisms of myocardial p38 mitogen-activated protein kinase activation: Evidence for MKKindependent activation by a tab1-associated mechanism contributing to injury during myocardial ischemia. Circ Res. 2003;93:254-261.
28. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001;345:1473-1482.
29. Camm AJ, Pratt CM, Schwartz PJ, et al. Mortality in patients after a recent myocardial infarction: A randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation. 2004;109:990-996.
30. Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581-2588.
31. Salameh A, Krautblatter S, Baessler S, et al. Signal transduction and transcriptional control of cardiac connexin43 up-regulation after alpha 1-adrenoceptor stimulation. J Pharmacol Exp Ther. 2008;326: 315-322.
32. Peters NS, Coromilas J, Severs NJ, et al. Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia. Circulation. 1997;95:988-996.
33. Saffitz JE, Schuessler RB, Yamada KA. Mechanisms of remodeling of gap junction distributions and the development of anatomic substrates of arrhythmias. Cardiovasc Res. 1999;42:309-317.
34. Naitoh K, Yano T, Miura T, et al. Roles of Cx43-associated protein kinases in suppression of gap junction-mediated chemical coupling by ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2009;296: H396-403.
35. Rohde S, Sabri A, Kamasamudran R, et al. The alpha(1)-adrenoceptor subtype- and protein kinase c isoform-dependence of norepinephrine's actions in cardiomyocytes. J Mol Cell Cardiol. 2000;32: 1193-1209.
36. Schluter KD, Simm A, Schafer M, et al. Early response kinase and PI 3-kinase activation in adult cardiomyocytes and their role in hypertrophy. Am J Physiol. 1999;276:H1655-1663.
37. Srisakuldee W, Jeyaraman MM, Nickel BE, et al. Phosphorylation of connexin-43 at serine 262 promotes a cardiac injury-resistant state. Cardiovasc Res. 2009;83:672-681.
38. Miura T, Yano T, Naitoh K, et al. Delta-opioid receptor activation before ischemia reduces gap junction permeability in ischemic myocardium by PKC-epsilon-mediated phosphorylation of connexin 43. Am J Physiol Heart Circ Physiol. 2007;293:H1425-1431.
39. Liao P, Wang SQ, Wang S, et al. P38 mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circ Res. 2002; 90:190-196.
40. Crow MT. Revisiting p53 and its effectors in ischemic heart injury. Cardiovasc Res. 2006;70:401-403.
41. Stephanou A, Brar BK, Scarabelli TM, et al. Ischemia-induced stat-1 expression and activation play a critical role in cardiomyocyte apoptosis. J Biol Chem. 2000;275:10002-10008.
42. Szegezdi E, Duffy A, O'Mahoney ME, et al. ER stress contributes to ischemia-induced cardiomyocyte apoptosis. Biochem Biophys Res Commun. 2006;349:1406-1411.
43. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359:473-481.
44. Ibanez B, Fuster V, Jimenez-Borreguero J, et al. Lethal myocardial reperfusion injury: A necessary evil? Int J Cardiol. 2011;151:3-11.
45. Naoi M, Maruyama W. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Expert Rev Neurother. 2009;9:1233-1250.